On April 10, 2026, the South China Morning Post reported significant investments in China’s biopharmaceutical sector, with Singaporean and Abu Dhabi sovereign wealth funds collaborating with Chinese state capital. A notable development is Shanghai’s Everest Medicines acquiring Singapore’s Hasten Biopharmaceutical for $250 million, gaining rights to 14 treatments for chronic diseases across the Asia-Pacific. This acquisition comes amidst a record surge of $60 billion in cross-border out-licensing deals by Chinese drugmakers in Q1 2026, driven by strong demand for early-stage assets from multinational firms. Additionally, Syneron Bio raised $150 million for its AI-driven drug discovery platform, reflecting the increasing global interest in Chinese biotechnology.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/cross-border-biotech-licensing-hits-record-60b-in-q1-2026/
